BRPI0519744A2 - metanonas de fenila substituÍda por sulfanila como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distérbios neurolàgicos e neuropsiquiÁtricos - Google Patents

metanonas de fenila substituÍda por sulfanila como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distérbios neurolàgicos e neuropsiquiÁtricos

Info

Publication number
BRPI0519744A2
BRPI0519744A2 BRPI0519744-9A BRPI0519744A BRPI0519744A2 BR PI0519744 A2 BRPI0519744 A2 BR PI0519744A2 BR PI0519744 A BRPI0519744 A BR PI0519744A BR PI0519744 A2 BRPI0519744 A2 BR PI0519744A2
Authority
BR
Brazil
Prior art keywords
lower alkyl
treatment
glyt
neuropsychiatric disorders
sulfanyl
Prior art date
Application number
BRPI0519744-9A
Other languages
English (en)
Inventor
Synese Jolidon
Roger David Norcross
Emmanuel Pinard
Robert Narquizian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0519744A2 publication Critical patent/BRPI0519744A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

METANONAS DE FENILA SUBSTITUÍDA POR SULFANILA COMO INIBIDORES DE TRANSPORTADOR DE GLICINA 1 (GLYT-1) PARA O TRATAMENTO DE DISTéRBIOS NEUROLàGICOS E NEUROPSIQUIÁTRICOS. A presente invenção refere-se aos compostos da fórmula geral em que R¹ é alquila inferior ou alquila inferior substituida por halogênio; R² é -S(O)~ 2~-alquila inferior, -S(O)~ 2~NH-alquila inferior, NO~ 2~ ou CN; Rü é halogênio, CN, alquila inferior, alquila inferior substituida por halogênio, NO~ 2~, -0(O)-alquila inferior ou S(O)~ 2~-alquila inferior; X/X¹ são independentemente um do outro CR^ 4^ ou N; R^ 4^ é hidrogênio ou halogênio; n é 0,1 ou 2; e aos sais de adição de ácido farmaceuticamente aceitáveis destes. Foi descoberto que os compostos de fórmula geral I são bons inibidores do transportador de glicina 1 (GIyT-1) para o tratamento de esquizofrenia.
BRPI0519744-9A 2005-01-06 2005-12-28 metanonas de fenila substituÍda por sulfanila como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distérbios neurolàgicos e neuropsiquiÁtricos BRPI0519744A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05100066 2005-01-06
PCT/EP2005/014081 WO2006072435A1 (en) 2005-01-06 2005-12-28 Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
BRPI0519744A2 true BRPI0519744A2 (pt) 2009-03-10

Family

ID=35976714

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519744-9A BRPI0519744A2 (pt) 2005-01-06 2005-12-28 metanonas de fenila substituÍda por sulfanila como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distérbios neurolàgicos e neuropsiquiÁtricos

Country Status (16)

Country Link
US (2) US20060149062A1 (pt)
EP (1) EP1836178A1 (pt)
JP (1) JP2008526795A (pt)
KR (1) KR20070094955A (pt)
CN (1) CN101356163A (pt)
AR (1) AR053659A1 (pt)
AU (1) AU2005324023A1 (pt)
BR (1) BRPI0519744A2 (pt)
CA (1) CA2593453A1 (pt)
IL (1) IL184355A0 (pt)
MX (1) MX2007008190A (pt)
NO (1) NO20073330L (pt)
RU (1) RU2007125380A (pt)
TW (1) TW200635911A (pt)
WO (1) WO2006072435A1 (pt)
ZA (1) ZA200705469B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008223915B2 (en) * 2007-03-05 2013-05-02 F. Hoffmann-La Roche Ag Process for the synthesis of GLYT-1 inhibitors
BRPI0920306A2 (pt) 2008-10-09 2019-09-24 Hoffmann La Roche derivados de n-benzil pirrolidina
US8153653B2 (en) * 2010-06-22 2012-04-10 Hoffmann-La Roche Inc. Amido-tropane derivatives
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
CN103254127B (zh) * 2013-05-28 2015-08-19 北京哈三联科技有限责任公司 甘氨酸重摄取抑制剂及其应用
MX2023001818A (es) 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2423847A1 (de) * 1973-05-28 1975-01-02 Ciba Geigy Ag Neue sulfamoylbenzoesaeureamide
DE2611705A1 (de) * 1976-03-18 1977-09-22 Josef Dipl Chem Dr Rer N Klosa N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel
PL343435A1 (en) * 1998-03-06 2001-08-13 Janssen Pharmaceutica Nv Glycine transport inhibitors
EP1296950A2 (en) * 2000-04-20 2003-04-02 NPS Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors
WO2004037800A1 (en) * 2002-10-22 2004-05-06 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
RS53252B (sr) * 2003-08-11 2014-08-29 F.Hoffmann-La Roche Ag. Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
WO2005023261A1 (en) * 2003-09-09 2005-03-17 F. Hoffmann-La Roche Ag 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
CN1874777B (zh) * 2003-09-09 2012-07-04 弗·哈夫曼-拉罗切有限公司 作为甘氨酸摄取抑制剂用于治疗精神病的1-(2-氨基-苯甲酰基)-哌嗪衍生物

Also Published As

Publication number Publication date
KR20070094955A (ko) 2007-09-27
ZA200705469B (en) 2008-11-26
AR053659A1 (es) 2007-05-16
JP2008526795A (ja) 2008-07-24
US20080287455A1 (en) 2008-11-20
US20060149062A1 (en) 2006-07-06
CN101356163A (zh) 2009-01-28
RU2007125380A (ru) 2009-02-20
AU2005324023A1 (en) 2006-07-13
NO20073330L (no) 2007-07-20
WO2006072435A1 (en) 2006-07-13
MX2007008190A (es) 2007-08-07
CA2593453A1 (en) 2006-07-13
IL184355A0 (en) 2007-10-31
TW200635911A (en) 2006-10-16
EP1836178A1 (en) 2007-09-26

Similar Documents

Publication Publication Date Title
BRPI0519794A2 (pt) derivados de [4-(heteroaril)piperazin-1-il]-(fenil 2,5-substituìdo)metanona como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distúrbios neurológicos e neuropsiquiátricos
BR0311494A (pt) Novos indóis substituìdos
EA200501585A1 (ru) Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами
PT2192109E (pt) Derivado de -aminoácido bicíclico
EA200401282A1 (ru) Пиридиноилпиперидины как агонисты 5-ht1f
MY153045A (en) Oxopyrazine derivative and herbicide
MX2007006896A (es) Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer.
WO2008108380A3 (en) Pyrrole compounds
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
PH12012500690A1 (en) Positive allosteric modulators (pam)
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
BRPI0517232A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
BRPI0519744A2 (pt) metanonas de fenila substituÍda por sulfanila como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distérbios neurolàgicos e neuropsiquiÁtricos
BRPI0518615A2 (pt) derivados de malonamida
ATE449082T1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
MX2009010243A (es) Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
BRPI0414597A (pt) derivados de benzofurano do tipo carbamoìla
BR0113348A (pt) Pró-drogas para ligantes de receptores de nmda
BRPI0514077A (pt) derivados de benzilóxi como inibidores de maob

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 5A E 6A ANUIDADES.